R
Robert D. McQuade
Researcher at Bristol-Myers Squibb
Publications - 70
Citations - 6385
Robert D. McQuade is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Aripiprazole & Tolerability. The author has an hindex of 34, co-authored 69 publications receiving 5894 citations. Previous affiliations of Robert D. McQuade include University of Minnesota.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
John M. Kane,William H. Carson,A. Saha,Robert D. McQuade,Gary G. Ingenito,Dan L. Zimbroff,Mirza Ali +6 more
TL;DR: Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.
Journal ArticleDOI
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
Stephen R. Marder,Robert D. McQuade,Elyse Stock,Stephen Kaplita,Ronald N. Marcus,Allan Z. Safferman,A. Saha,Mirza Ali,Taro Iwamoto +8 more
TL;DR: Aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation and may offer benefits in schizophrenia treatment.
Journal ArticleDOI
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : A multicenter, randomized, double-blind, placebo-controlled study
Robert M. Berman,Ronald N. Marcus,Rene Swanink,Robert D. McQuade,William H. Carson,Patricia K. Corey-Lisle,Arif Ullah Khan +6 more
TL;DR: In patients with MDD who showed an incomplete response to ADT, adjunctive aripiprazole was efficacious and well tolerated.
Journal ArticleDOI
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres,Arlene B. Chapman,Olivier Devuyst,Olivier Devuyst,Ron T. Gansevoort,Ronald D. Perrone,Gary G. Koch,John Ouyang,Robert D. McQuade,Jaime D. Blais,Frank S. Czerwiec,Olga Sergeyeva,Reprise Trial Investigators +12 more
TL;DR: Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1‐year period in patients with later‐stage ADPKD, and Elevations in the aminotransferase level were reversible after stopping tolvaptan.
Journal ArticleDOI
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Ronald N. Marcus,Robert D. McQuade,William H. Carson,Delphine Hennicken,Maurizio Fava,Jeffrey S. Simon,Madhukar H. Trivedi,Michael E. Thase,Robert M. Berman +8 more
TL;DR: Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT.